Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$756.81 -25.70 (-3.28%)

(As of 11/15/2024 08:54 PM ET)

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
1

Hold
4

Buy
18

Based on 23 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 4 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for REGN.

Consensus Price Target

$1,099.55
45.29% Upside

According to the 23 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $1,099.55. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $720.00. The average price target represents a forecasted upside of 45.29% from the current price of $756.81.

REGN Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	17 Buy rating(s)	19 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$1,099.55	$1,116.00	$1,097.05	$903.64
Forecasted Upside	45.29% Upside	12.65% Upside	-7.98% Downside	12.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	45.29% Upside	28,591.96% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent REGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Wolfe Research 3 of 5 stars		Initiated Coverage	Outperform	$1,150.00	+46.96%
11/14/2024	Citigroup 3 of 5 stars		Initiated Coverage	Neutral	$895.00	+11.27%
11/6/2024	Oppenheimer 3 of 5 stars		Lower Target	Outperform ➝ Outperform	$1,150.00 ➝ $1,000.00	+20.56%
11/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,260.00 ➝ $1,215.00	+44.97%
11/1/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,235.00 ➝ $1,184.00	+41.27%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,080.00 ➝ $1,065.00	+25.91%
The Harvard Business School proved his stock picking system works (Ad) If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it. Follow this link here we’ll add you to the guest list.
11/1/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$1,300.00 ➝ $1,190.00	+40.24%
11/1/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$1,137.00 ➝ $1,126.00	+33.88%
11/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,242.00 ➝ $1,195.00	+42.57%
10/24/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$1,250.00 ➝ $1,175.00	+24.93%
10/24/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,150.00	+22.16%
10/23/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$1,015.00 ➝ $1,015.00	+7.77%
10/22/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,050.00	+9.11%
9/24/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$1,175.00 ➝ $1,077.00	-1.37%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,180.00 ➝ $1,300.00	+19.90%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,030.00 ➝ $1,200.00	+12.39%
6/27/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$1,152.00 ➝ $1,152.00	+7.78%
6/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,170.00	+9.97%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,090.00 ➝ $1,099.00	+21.95%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$710.00 ➝ $720.00	-21.77%
3/12/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,125.00	+16.65%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$800.00 ➝ $760.00	+6.13%
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%
3/28/2023	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$853.00 ➝ $862.00	+14.73%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	+17.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:32 AM ET.

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 30, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

Regeneron Pharmaceuticals has a strong average rating of "Moderate Buy" with a consensus target price of $1,118.62, indicating positive sentiment from analysts.
Recent insider activity shows that the chief financial officer sold shares at a higher price, potentially signaling confidence in the company's future performance.
Institutional inflows have been observed, with various funds increasing their positions in Regeneron Pharmaceuticals, indicating institutional investor confidence in the company.
The stock price of Regeneron Pharmaceuticals has shown resilience, trading at $1,042.69 on the NASDAQ, reflecting stability and potential growth.
Regeneron Pharmaceuticals continues to innovate and develop medicines for various diseases globally, showcasing a commitment to research and development.

Regeneron Pharmaceuticals
Bear Case

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

Multiple analysts have issued hold ratings on Regeneron Pharmaceuticals, potentially indicating uncertainty or limited short-term growth prospects.
Recent insider selling activity has been notable, with insiders selling a significant number of shares, which could raise concerns about insider sentiment.
While institutional inflows have been observed, the percentage of stock owned by institutional investors is relatively high at 83.31%, potentially limiting individual investor influence.
The PE ratio of 31.20 and price-to-earnings-growth ratio of 3.72 may suggest that the stock is currently trading at a premium, which could impact potential returns for investors.
The beta of 0.12 indicates low volatility compared to the market, which may limit short-term trading opportunities for investors seeking higher volatility stocks.

REGN Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $1,099.55, with a high forecast of $1,300.00 and a low forecast of $720.00.
: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There is currently 1 sell rating, 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.
: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 45.29% based on their 12-month stock forecasts.
: Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 upgrades and 1 downgrade by analysts.
: Regeneron Pharmaceuticals has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Oppenheimer, Piper Sandler, Royal Bank of Canada, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Regeneron Pharmaceuticals less than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.78 while the average consensus rating score for "medical" companies is 2.80. Learn more on how REGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The Harvard Business School proved his stock picking system works (Ad)

Follow this link here we’ll add you to the guest list.

This page (NASDAQ:REGN) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target